Richard Nicoletti

发表

High-throughput oncogene mutation profiling in human cancer

S. Gabriel, S. Nelson, M. Meyerson, 2007, Nature Genetics.

Subtype-specific genomic alterations define new targets for soft tissue sarcoma therapy

Derek Y. Chiang, T. Fennell, K. Cibulskis, 2010, Nature Genetics.

MAP 3 K 11 / GDF 15 axis is a critical driver of cancer cachexia

A. Vigano, Richard Nicoletti, S. Weiler, 2015 .

Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients

Richard Nicoletti, J. Gyuris, T. Hayes, 2015, Journal of cachexia, sarcopenia and muscle.

Growth differentiating factor-15 (GDF-15): A potential biomarker and therapeutic target for cancer-associated weight loss.

Richard Nicoletti, J. Gyuris, A. Jatoi, 2016, Oncology letters.

23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity

Richard Nicoletti, L. Poling, S. Weiler, 2015, Molecular Cancer Therapeutics.

Neuregulin 1 Expression Is a Predictive Biomarker for Response to AV-203, an ERBB3 Inhibitory Antibody, in Human Tumor Models

Richard Nicoletti, S. Weiler, J. Gyuris, 2014, Clinical Cancer Research.

Drug-sensitive FGFR2 mutations in endometrial carcinoma

Kristian Cibulskis, Wendy Winckler, Michael C Zody, 2008, Proceedings of the National Academy of Sciences.

MAP3K11/GDF15 axis is a critical driver of cancer cachexia

A. Vigano, Richard Nicoletti, S. Weiler, 2015, Journal of cachexia, sarcopenia and muscle.

Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer

S. Gabriel, S. Nelson, M. Meyerson, 2007 .